Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
Status:
Recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
To date, the benefit of intravenous thrombolysis is confined within 4.5 hours of onset for
acute ischemic stroke (AIS) patients without advanced neuroimaging selection. Unpublished
pilot EXIT-BT (EXtending the tIme window of Thrombolysis by ButylphThalide up to 6 Hours
after onset) suggest the safety, feasibility and potential benefit of intravenous
tenecteplase (TNK) in AIS within 4.5 to 6 hours of onset. The current study aims to
investigate the efficacy and safety of TNK for AIS within 4.5 to 6 hours of onset.